{
    "2020-07-04": [
        [
            {
                "time": "",
                "original_text": "红刊雪球秀｜百创资本陈子仪：医药整体估值偏高但不乏低估品，疫苗、CRO还有很大成长空间",
                "features": {
                    "keywords": [
                        "医药",
                        "估值",
                        "疫苗",
                        "CRO",
                        "成长空间"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}